|
nasdaq:wve
|
5165934
|
Apr 21st, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
309.00
|
Open
|
|
Apr 21st, 2024 03:28AM
|
Apr 21st, 2024 03:28AM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 20th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
309.00
|
Open
|
|
Apr 20th, 2024 12:33AM
|
Apr 20th, 2024 05:51PM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 19th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
310.00
|
Open
|
|
Apr 19th, 2024 04:51AM
|
Apr 19th, 2024 04:51AM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 18th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
310.00
|
Open
|
|
Apr 18th, 2024 01:31AM
|
Apr 18th, 2024 07:11PM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 17th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
311.00
|
Open
|
|
Apr 17th, 2024 04:29AM
|
Apr 17th, 2024 03:38PM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 16th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
310.00
|
Open
|
|
Apr 16th, 2024 12:20AM
|
Apr 16th, 2024 11:54AM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 15th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
310.00
|
Open
|
|
Apr 15th, 2024 05:07AM
|
Apr 15th, 2024 05:35PM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 14th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
311.00
|
Open
|
|
Apr 13th, 2024 11:55PM
|
Apr 14th, 2024 11:53AM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 13th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
311.00
|
Open
|
|
Apr 12th, 2024 11:46PM
|
Apr 13th, 2024 12:20PM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:wve
|
5165934
|
Apr 12th, 2024 12:00AM
|
Wave Life Sciences
|
15K
|
311.00
|
Open
|
|
Apr 11th, 2024 11:53PM
|
Apr 12th, 2024 09:16AM
|
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity.
Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
|
Open
|
Biotechnology, Oligonucleotides, Genetic medicines, RNA editing, and RNAi
|
Open
|
733 Concord Avenue
|
Cambridge
|
Massachusetts
|
US
|
02138
|
|
WAVE Life Sciences
|
Health Care
|
Pharmaceuticals & Biotechnology
|